BPC-157
Also known as: BPC 157, Body Protection Compound-157, Pentadecapeptide
Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
BPC-157 is derived from a protein naturally found in human gastric juice. While it accelerates healing of tendons, ligaments, and gut tissue through angiogenesis and nitric oxide modulation, it does not affect hormones, strength, or muscle mass. Effects are therapeutic/recovery-focused rather than performance-enhancing. No PCT required. Extensive animal data but limited human clinical trials. Rated 1 (basically natty) because it only restores you toward baseline through faster healing. It does not raise the muscular/physique/performance ceiling by any path.
Overview
A peptide derived from a protein found in stomach acid with profound tissue-healing properties. Used for healing tendons, ligaments, gut inflammation, and various injuries.
Important Warnings
- •Limited human clinical data - efficacy is extrapolated mostly from animal studies
- •Quality varies significantly between sources
- •FDA placed BPC-157 on the Category 2 bulk-substances list (2023), so compounding pharmacies can no longer legally make it - supply is now the unregulated research/gray market (its 503A status remains under FDA review)
Purpose & Use Cases
Tendon & Ligament Healing
Accelerates healing of tendon and ligament injuries significantly.
Gut Healing
Repairs gut lining and helps with various GI issues including IBD.
Muscle Healing
Promotes faster recovery from muscle injuries.
Joint Recovery
Supports joint health and recovery from joint injuries.
Benefits
- Accelerated tendon and ligament healing
- Gut repair and protection
- Enhanced wound healing
- Anti-inflammatory effects
- Neuroprotective properties
- Very safe profile
Good to Know
The local half of the 'Wolverine' stack
BPC-157 + TB-500 is the classic 'Wolverine' healing stack. The division of labor: BPC-157 is typically injected near the injury for site-specific tendon, ligament, and gut repair (local angiogenesis + growth-factor signaling), while TB-500 works systemically throughout the body. Running both is meant to cover local and whole-body healing at once.
FDA restricted it in 2023 (Category 2)
In 2023 the FDA placed BPC-157 on its Category 2 bulk-substances list, barring licensed compounding pharmacies from legally preparing it, supply shifted almost entirely to the unregulated research/gray market. Its 503A bulk-substance status remains under FDA review and may change. Note it is a common name, not an official USAN, which the FDA flagged as its own risk.
Healing, not performance: and not hormonal
BPC-157 does not touch the HPTA, does not aromatize, and produces no direct muscle, strength, or fat-loss effect. It works by accelerating repair (angiogenesis, nitric-oxide modulation, local upregulation of growth-hormone receptors in tendon). That is why it rates a 2 on the natty scale, genuinely useful for recovery, but not an anabolic.
The evidence is almost all animal
The dramatic tendon/ligament/gut-healing results come overwhelmingly from rodent studies. Controlled human trials are minimal, so real-world dosing and efficacy are extrapolated from animal data and community experience, the enthusiasm currently outruns the clinical evidence.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 250 – 250 mcg/day |
| Intermediate | 250 – 500 mcg/day |
| Advanced | 500 – 500 mcg/day |
Can be injected locally near injury site or systemically. Oral form available for gut healing.
<30 minutes (elimination half-life, rat IV/IM PK data); no human PK studies exist, and biological/healing effects are believed to outlast measurable plasma presence.
Side Effects
Nausea
rareOccasional nausea, typically mild.
Take with food if using oral form.
Headache
rareOccasional mild headaches.
Usually transient; reduce dose if persistent.
General Mitigation Strategies
BPC-157 has an excellent safety profile. Use sterile injection technique. Side effects are rare and mild. Largely unstudied in humans, though animal data is extensive.
Support Supplements
Ancillary supplements commonly run alongside BPC-157 to manage side effects, support the target tissue, or fill nutrient demands it creates.
Hydrolyzed collagen / gelatin + vitamin C
Supplies the glycine/proline building blocks and the vitamin C cofactor (for prolyl/lysyl hydroxylase) that collagen synthesis needs. BPC-157 signals tendon/ligament fibroblasts to repair; this provides the raw material to actually build matrix.
- Dose
- ~15g collagen/gelatin + ~50-200mg vitamin C
- Timing
- Take ~30-60 minutes before rehab/loading of the injured tissue (based on Baar/Shaw connective-tissue research)
- When
- Most relevant when BPC-157 is used for tendon, ligament, or other connective-tissue healing rather than gut-only use.
Adequate protein intake
General substrate for tissue repair: healing is protein-synthesis limited, so a peptide signal does little if daily protein is low.
- Dose
- ~1.6-2.2 g/kg/day
- Timing
- Spread across the day
Post Cycle Therapy (PCT)
Does not affect hormones. No PCT required.
How It Works
BPC-157 promotes angiogenesis (new blood vessel formation), upregulates growth hormone receptors, and modulates nitric oxide synthesis. It accelerates the healing of many different wound types and has protective effects on the GI tract.
Fundamentals
Reference on the practices relevant to BPC-157: how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- BPC-157 + TB-500 - "Wolverine" healing stack
- BPC-157 + GHK-Cu - Comprehensive tissue repair
WADA Status
BPC-157 has been prohibited by WADA under S0 (non-approved substances) at all times since 2022. Its stack-partner TB-500 is also prohibited (S2). Contamination risk also exists with research chemicals.
References
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide, Literature and Patent Review (PMC11859134)
- Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT), Inflammopharmacology, 2025 (PMC12396989)
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs, Frontiers in Pharmacology, 2022 (PMC9794587)